Australia’s major listed pharmaceutical company faces a steep market downturn, with reports describing an $88 billion reduction in value that marks a significant investing “bloodbath.” Multiple outlets frame the losses as part of a wider set of challenges rather than solely stemming from Donald Trump-related developments, arguing that the company’s performance reflects issues beyond US political policy. The articles present the company as a long-standing success story that has instead become a major source of investor concern, emphasizing the scale and historic nature of the decline. While the pieces do not converge on a single detailed cause, they share the view that the drawdown is large enough to indicate structural or operational pressures impacting valuation, and that external factors are only part of the picture. Overall, the coverage highlights investor unease and the magnitude of the sell-off, portraying the situation as a turning point for one of Australia’s most prominent healthcare businesses and its shareholders.